These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 11738080)
1. Changes in blood viscosity by heparin and argatroban. Hitosugi M; Niwa M; Takatsu A Thromb Res; 2001 Dec; 104(5):371-4. PubMed ID: 11738080 [TBL] [Abstract][Full Text] [Related]
2. The effects of argatroban on thrombin generation and hemostatic activation in vitro. Tanaka KA; Szlam F; Katori N; Sato N; Vega JD; Levy JH Anesth Analg; 2004 Nov; 99(5):1283-1289. PubMed ID: 15502018 [TBL] [Abstract][Full Text] [Related]
3. Activity of a sub-cutaneously administered novel mixed micellar formulation of argatroban in rat and rabbit models of venous thrombosis. Berry CN; Visconte C; Lecoffre C; Lochot S; Girard D Thromb Haemost; 2000 Aug; 84(2):286-90. PubMed ID: 10959702 [TBL] [Abstract][Full Text] [Related]
4. Antithrombotic actions of the thrombin inhibitor, argatroban, in a canine model of coronary cyclic flow: comparison with heparin. Duval N; Lunven C; O'Brien DP; Grosset A; O'Connor SE; Berry CN Br J Pharmacol; 1996 Jun; 118(3):727-33. PubMed ID: 8762100 [TBL] [Abstract][Full Text] [Related]
5. Antithrombotic actions of argatroban in rat models of venous, 'mixed' and arterial thrombosis, and its effects on the tail transection bleeding time. Berry CN; Girard D; Lochot S; Lecoffre C Br J Pharmacol; 1994 Dec; 113(4):1209-14. PubMed ID: 7889274 [TBL] [Abstract][Full Text] [Related]
6. BCH-2763, a novel potent parenteral thrombin inhibitor, is an effective antithrombotic agent in rodent models of arterial and venous thrombosis--comparisons with heparin, r-hirudin, hirulog, inogatran and argatroban. Finkle CD; St Pierre A; Leblond L; Deschenes I; DiMaio J; Winocour PD Thromb Haemost; 1998 Feb; 79(2):431-8. PubMed ID: 9493603 [TBL] [Abstract][Full Text] [Related]
7. Antithrombotic effects of YM-60828, a newly synthesized factor Xa inhibitor, in rat thrombosis models and its effects on bleeding time. Sato K; Kawasaki T; Hisamichi N; Taniuchi Y; Hirayama F; Koshio H; Matsumoto Y Br J Pharmacol; 1998 Jan; 123(1):92-6. PubMed ID: 9484858 [TBL] [Abstract][Full Text] [Related]
8. The direct thrombin inhibitor argatroban effectively prevents cardiac catheter thrombosis in vitro. Raaz U; Kaeberich A; Maegdefessel L; Buerke M; Busshardt M; Schubert S; Russ M; Plehn A; Ebelt H; Werdan K; Schlitt A Thromb Haemost; 2010 Apr; 103(4):808-14. PubMed ID: 20174756 [TBL] [Abstract][Full Text] [Related]
9. Argatroban, bivalirudin, and lepirudin do not decrease clot propagation and strength as effectively as heparin-activated antithrombin in vitro. Nielsen VG; Steenwyk BL; Gurley WQ; Pereira SJ; Lell WA; Kirklin JK J Heart Lung Transplant; 2006 Jun; 25(6):653-63. PubMed ID: 16730571 [TBL] [Abstract][Full Text] [Related]
10. Antithrombotic and hemorrhagic effects of DX-9065a, a direct and selective factor Xa inhibitor: comparison with a direct thrombin inhibitor and antithrombin III-dependent anticoagulants. Morishima Y; Tanabe K; Terada Y; Hara T; Kunitada S Thromb Haemost; 1997 Nov; 78(5):1366-71. PubMed ID: 9408021 [TBL] [Abstract][Full Text] [Related]
11. Thrombin generation assay and viscoelastic coagulation monitors demonstrate differences in the mode of thrombin inhibition between unfractionated heparin and bivalirudin. Tanaka KA; Szlam F; Sun HY; Taketomi T; Levy JH Anesth Analg; 2007 Oct; 105(4):933-9, table of contents. PubMed ID: 17898368 [TBL] [Abstract][Full Text] [Related]
12. Synergistic antithrombotic properties of G4120, a RGD-containing synthetic peptide, and argatroban, a synthetic thrombin inhibitor, in a hamster femoral vein platelet-rich thrombosis model. Imura Y; Stassen JM; Vreys I; Lesaffre E; Gold HK; Collen D Thromb Haemost; 1992 Sep; 68(3):336-40. PubMed ID: 1440501 [TBL] [Abstract][Full Text] [Related]
13. Changes in blood viscosity with synthetic protease inhibitors. Hitosugi M; Niwa M; Takahashi T; Kurosu A; Nihei H; Nagai T; Tokudome S J Pharmacol Sci; 2003 Apr; 91(4):334-6. PubMed ID: 12719663 [TBL] [Abstract][Full Text] [Related]
14. Effects of argatroban and heparin on thrombus formation and tissue plasminogen activator-induced thrombolysis in a microvascular thrombosis model. Yamada K; Tsuji H; Kimura S; Kato H; Yano S; Ukimura N; Yamada Y; Nakagawa K; Nakagawa M Thromb Res; 2003 Jan; 109(1):55-64. PubMed ID: 12679132 [TBL] [Abstract][Full Text] [Related]
15. Argatroban: update. Yeh RW; Jang IK Am Heart J; 2006 Jun; 151(6):1131-8. PubMed ID: 16781211 [TBL] [Abstract][Full Text] [Related]
16. Antithrombotic potential of new direct thrombin inhibitors built on the azaphenylalanine scaffold in two rat venous thrombosis models. Peternel L; Stegnar M; Drevensek G; Budihna MV; Bozic M; Zega A; Stalc A; Cerne M; Urleb U Thromb Haemost; 2005 Mar; 93(3):437-42. PubMed ID: 15735792 [TBL] [Abstract][Full Text] [Related]
17. Argatroban enhances fibrinolysis by differential inhibition of thrombin-mediated activation of thrombin activatable fibrinolysis inhibitor and factor XIII. Nielsen VG; Kirklin JK Blood Coagul Fibrinolysis; 2008 Dec; 19(8):793-800. PubMed ID: 19002046 [TBL] [Abstract][Full Text] [Related]
18. Changes in blood viscosity with mucopolysaccharide polysulfate. Hitosugi M; Omura K; Kido M; Kawato H; Niwa M; Nagai T; Tokudome S J Pharmacol Sci; 2004 May; 95(1):132-4. PubMed ID: 15153660 [TBL] [Abstract][Full Text] [Related]
19. Antithrombotic activity of argatroban in experimental thrombosis in the rabbit. Berry CN; Girard D; Girardot C; Lochot S; Lunven C; Visconte C Semin Thromb Hemost; 1996; 22(3):233-41. PubMed ID: 8836007 [TBL] [Abstract][Full Text] [Related]
20. Effects of the synthetic thrombin inhibitor argatroban on fibrin- or clot-incorporated thrombin: comparison with heparin and recombinant Hirudin. Berry CN; Girardot C; Lecoffre C; Lunven C Thromb Haemost; 1994 Sep; 72(3):381-6. PubMed ID: 7855788 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]